论文部分内容阅读
目的:探讨参附注射液对老年慢性心衰患者脑钠肽(NT-proBNP)、心脏型脂肪酸结合蛋白(H-FABP)及C-反应蛋白(CRP)的影响。方法:收集我院收治的慢性心力衰竭患者70例,随机分为对照组和实验组,每组各35例,对照组患者均给予相应常规对症治疗,实验组患者在对照组基础上给予参附注射液静脉滴注,治疗结束后观察并比较两组患者治疗前后血清NT-proBNP、H-FABP及CRP水平的变化以及治疗效果。结果:与治疗前相比,两组患者治疗后血清NT-proBNP、H-FABP及CRP水平与治疗前相比均降低(P<0.05);实验组患者治疗后血清NT-proBNP、H-FABP及CRP水平与对照组患者相比较低(P<0.05)。实验组临床总有效率与对照组相比较高,但差异无统计学意义(P>0.05)。结论:参附注射液能够降低老年慢性心衰患者血清NT-proBNP、H-FABP及CRP水平,提高临床疗效。
Objective: To investigate the effect of Shenfu injection on brain natriuretic peptide (NT-proBNP), cardiac fatty acid binding protein (H-FABP) and C-reactive protein (CRP) in elderly patients with chronic heart failure. Methods: Seventy patients with chronic heart failure admitted to our hospital were randomly divided into control group and experimental group with 35 cases in each group. Patients in control group were given corresponding conventional symptomatic treatment. Patients in experimental group were given Shenfu Injection intravenous drip, after treatment was observed and compared two groups of patients before and after treatment, serum NT-proBNP, H-FABP and CRP level changes and the therapeutic effect. Results: Compared with those before treatment, the serum levels of NT-proBNP, H-FABP and CRP were lower in both groups after treatment (P <0.05). The levels of serum NT-proBNP and H-FABP And CRP levels were lower than those in the control group (P <0.05). The total effective rate of the experimental group was higher than that of the control group, but the difference was not statistically significant (P> 0.05). Conclusion: Shenfu injection can reduce serum NT-proBNP, H-FABP and CRP levels in elderly patients with chronic heart failure, and improve clinical efficacy.